Publications by authors named "Jean Marc Girard"
Background: Immunosenescence is accelerated by chronic infectious and autoimmune diseases and could contribute to the pathobiology of multiple sclerosis (MS). How MS and disease-modifying therapies (DMTs) impact age-sensitive immune biomarkers is only partially understood.
Methods: We analyzed 771 serum samples from 147 healthy controls and 289 people with MS (PwMS) by multiplex immunoassays.
Article Synopsis
- The global MS population is aging, with peak prevalence observed in individuals aged 55-65, leading to shifts in disease characteristics and progression.
- Aging impacts the pathophysiology of MS, causing a consistent worsening of disability around age 50, which is independent of prior disease duration.
- Older MS patients face unique challenges, such as diminished treatment efficacy, increased adverse effects from medications, and a higher burden of comorbidities, necessitating individualized treatment approaches.
Article Synopsis
- GM-CSF plays a significant role in chronic inflammatory diseases like multiple sclerosis (MS) by affecting myeloid cell functions, specifically monocyte-derived macrophages (MDMs) and microglia.
- The study found that GM-CSF increases IL-15 expression in MDMs from both healthy individuals and MS patients, as well as in human microglia, which may enhance the immune response against MS.
- Notably, while GM-CSF-stimulated MDMs elevate CD8 T lymphocytes' production of effector molecules, this enhancement occurs independently of IL-15, suggesting that GM-CSF influences myeloid cells through multiple pathways.